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Objective To assess the short- and long-term effects of
mindfulness-based stress reduction (MBSR) on the resulting
quality of life, sexual functioning, and sexual distress after risk-
reducing salpingo-oophorectomy (RRSO).
Design Randomised controlled trial.
Setting A specialised family cancer clinic of the university medical
center Groningen.
Population Sixty-six women carriers of the BRCA1/2 mutation
who developed at least two moderate-to-severe menopausal
symptoms after RRSO.
Methods Women were randomised to an 8-week MBSR training
programme or to care as usual (CAU).
Main outcome measures Change in the Menopause-Specific
Quality of Life Questionnaire (MENQOL), the Female Sexual
Function Index, and the Female Sexual Distress Scale,
administered from baseline at 3, 6, and 12 months. Linear mixed
modelling was applied to compare the effect of MBSR with CAU
over time.
Results At 3 and 12 months, there were statistically significant
improvements in the MENQOL for the MBSR group compared
with the CAU group (both P = 0.04). At 3 months, the mean
MENQOL scores were 3.5 (95% confidence interval, 95% CI 3.0–
3.9) and 3.8 (95% CI 3.3–4.2) for the MBSR and CAU groups,
respectively; at 12 months, the corresponding values were 3.6
(95% CI 3.1–4.0) and 3.9 (95% CI 3.5–4.4). No significant
differences were found between the MBSR and CAU groups in the
other scores.
Conclusion Mindfulness-based stress reduction was effective at
improving quality of life in the short- and long-term for patients
with menopausal symptoms after RRSO; however, it was not
associated with an improvement in sexual functioning or distress.
Keywords BRCA1/2, menopausal symptoms, mindfulness,
salpingo-oophorectomy, sexual functioning, surgical menopause.
Tweetable abstract Mindfulness improves menopause-related
quality of life in women after risk-reducing salpingo-
oophorectomy.
Please cite this paper as: van Driel CMG, de Bock GH, Schroevers MJ, Mourits MJ. Mindfulness-based stress reduction for menopausal symptoms after risk-
reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial. BJOG 2019;126:402–411.
Introduction
Women carrying a BRCA1 or BRCA2 mutation have an
increased lifetime risk of developing breast and ovarian
cancer, compared with the general population.1–4 At pre-
sent, because ovarian cancer screening is ineffective for
early detection, offering risk-reducing salpingo-oophorect-
omy (RRSO) is standard practice to reduce the incidence
of ovarian cancer in these women.5–8 RRSO is recom-
mended at the ages of 35–40 years for BRCA1 mutation
carriers and at 40–45 years for BRCA2 mutation carriers,
provided that there is no desire to have more children.9–
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13 There is good evidence that the procedure reduces the
risk of ovarian cancer by up to 96% when performed
within these age ranges.14–17
The acute surgical menopause induced by RRSO is asso-
ciated with sequelae, of which hot flashes, (night) sweats,
vaginal dryness, loss of sexual desire, and pain during inter-
course are the most frequent.18–27 Moreover, it is reported
that menopausal symptoms are more severe after acute sur-
gical menopause than after natural menopause.28 Although
hormone replacement therapy (HRT) can alleviate the
symptoms, they only do so partially, and symptom levels
remain above those of premenopausal women.22 Con-
founding this issue is the fact that one-third of BRCA1/2
mutation carriers who undergo RRSO have had breast can-
cer, contraindicating the use of HRT.29,30 Therefore, non-
hormonal methods are needed to alleviate the menopausal
symptoms induced by RRSO in breast cancer survivors.
A possible non-hormonal alternative could be a
psychological intervention that targets perception and
acceptance, such as mindfulness-based training. The goal
of such training is to help the patient pay full attention
to the present moment in a non-judgmental, accepting
way.31 Specifically, the mindfulness-based stress reduction
(MBSR) method achieves this through a well-described,
protocol-based training programme over an 8-week
period. The programme consists of meditation, gentle
yoga poses, and body awareness exercises. In studies
carried out in women experiencing menopausal symp-
toms after breast cancer treatment or natural menopause,
MBSR has shown promise for both reducing difficulty
with hot flushes and improving menopause-specific qual-
ity of life.32–35 These studies were not carried out in
women with RRSO-induced menopause, however, and
they were either uncontrolled or had short follow-up
periods.
In the present study, we aimed to investigate the short-
and long-term effects of MBSR compared with care as
usual (CAU) in BRCA1/2 mutation carriers after RRSO.
Specifically, we were interested in the effects on meno-
pause-specific quality of life (primary outcome) and on




The randomised controlled trial, ‘Psychosexual con-
seqUences of Risk-reducing Salpingo-oophorectomy in
BRCA1/2 mUtation carriErs’ (PURSUE) study is an open-
label trial and was approved by the Medical Ethical Com-
mittee of the University Medical Center Groningen on 14
November 2014 (registration no. NL46796.042.14). It was
conducted in accordance with the principles of the
Declaration of Helsinki (as amended in 2013) and the rele-
vant Dutch legislation (the Medical Research Involving
Human Subjects Act). The ClinicalTrials.gov identifier for
the trial is NCT02372864. Women were recruited for par-
ticipation from January 2015 to October 2015, and were
followed for 1 year after randomisation. Patients were not
involved in the development of the study.
Participants
The clinical data for women referred to the Family Cancer
Clinic of the University Medical Center Groningen for
being at increased risk of developing breast or ovarian
cancer, including BRCA1/2 mutation carriers, have been
prospectively recorded in a database since 1994.12 We
contacted BRCA1/2 mutation carriers who underwent
RRSO at an age younger than 52 years by letter, detailing
the possibility of receiving MBSR training aimed at allevi-
ating menopausal symptoms after RRSO. The letter
included a purpose-designed questionnaire (Appendix S1)
about the presence and severity of menopausal symptoms.
Cancer history and current psychiatric and cancer treat-
ment were recorded on the questionnaire. Women were
eligible for participation if they had undergone RRSO
before the age of 52 years and reported at least two mod-
erate-to-severe menopausal symptoms in the two preced-
ing weeks. We excluded the following groups: women
who were undergoing cancer treatment at the time of
inclusion, apart from those receiving adjuvant hormonal
or immune therapy; women who were receiving psychi-
atric care; and women who had an insufficient under-
standing of the Dutch language to complete the
questionnaires. We did not exclude women using HRT,
non-hormonal medications (e.g. clonidine), or dietary or
herbal remedies (e.g. soy or black cohosh), or women
with a history of breast cancer. All eligible women were
invited for an intake visit, and after giving written
informed consent, were randomised to an intervention or
to a control group. The intervention group received an 8-
week MBSR training course, plus CAU, whereas the con-
trol group only received CAU.
Interventions
Participants in the MBSR group received an 8-week MBSR
training course (Appendix S2). This comprised weekly ses-
sions of 2.5 hours each, a silent retreat evening lasting
4 hours, and a commitment to performing mindfulness
exercises at home for 30–45 minutes for 6 days of the week
using instructions provided on an MP3 player.31 The
MBSR training was a standard training programme and
was not specifically adapted to focus on menopausal symp-
toms. In total, six MBSR training classes were organised,
each with between four and seven study participants only.
Training classes took place at three locations in the north
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of the Netherlands to reduce the travel time for partici-
pants, and all were led by one of three certified and experi-
enced MBSR trainers.
Care as usual
Care as usual consisted of information provided by a spe-
cialist nurse during the intake visit. This covered lifestyle
advice for hot flashes, night sweats, vaginal dryness, sexual
functioning, cardiovascular health, and bone health. An
information booklet summarizing this information was
provided to participants in both groups. Approximately
12 weeks after randomisation, all participants were offered
a repeat appointment with the nurse to address any
remaining issues.
Randomisation
We used block randomization, stratified by HRT use. Ran-
domisation was performed by the independent trial coordi-
nation centre of the University Medical Center Groningen
via a web application, using a computerised random num-
ber generator. After randomisation, an email was automati-
cally sent to the research nurse and researchers detailing
the group allocation of that particular study participant.
The participants were informed about their allocation
group by the research nurse.
Assessments
Questionnaires were sent by mail at randomisation (T0,
baseline), and at 3 (T1), 6 (T2), and 12 months (T3) there-
after. If participants did not respond, a second request was
sent after 4 weeks and a third request was sent after
8 weeks. If no response was received after 12 weeks, or the
data were unclear, the participant was contacted by email
and/or phone by a researcher.
Baseline descriptive measures
The following baseline characteristics were collected: age,
weight, height, marital or cohabitating status, parity, num-
ber of children living at home, highest completed education
level, employment, smoking history, alcohol consumption,
exercise behaviour, breast cancer history, mastectomy his-
tory, and HRT use. In addition, anxiety and depression
were screened using the Generalized Anxiety Disorder 7
(GAD-7) questionnaire,36 and the Patient Health Question-
naire 2 (PHQ-2),37 respectively.
Primary outcome measure
The primary outcome of interest was menopause-specific
quality of life, as measured by the Menopause-specific
Quality of Life questionnaire (MENQOL). The MENQOL
is a self-administered 29-item questionnaire that assesses
the quality of life of menopausal women over the preceding
4 weeks.38 It records the presence and the severity of
menopausal symptoms as the degree of perceived burden
(or bother) that women experience from menopausal
symptoms, using a seven-point scale for each item. It con-
sists of four domains: vasomotor (three items), psychoso-
cial (seven items), physical (16 items), and sexual (three
items). The domain scores range from one to eight, with
one reflecting an absence of symptoms and eight reflecting
extremely bothersome symptoms. A cut-off score is not
available.
Secondary outcome measures
The Female Sexual Function Index (FSFI) questionnaire
consists of 19 items on six subdomains: desire, arousal,
lubrication, orgasm, satisfaction, and pain.39 Each domain
is scored on a Likert-type scale from zero to five. Higher
scores indicate better sexual functioning in the prior
4 weeks, and a score <26.55 indicates sexual dysfunction.40
Sexual distress was determined using the Female Sexual
Distress Scale (FSDS) questionnaire for the preceding
4 weeks. The FSDS consists of 12 items scored on a five-
point Likert scale from zero (no distress) to four (always
experiencing distress).41 A score of 11 or higher indicates
sexual distress.42
Sample size calculation
The minimum sample size was calculated as 64 with, and
60 without, correcting for a 10% rate of attrition, based on
a minimal clinically relevant difference of 1.0 on the MEN-
QOL, a standard deviation of 1.36 based on a previous ran-
domised controlled trial (RCT) that compared the change
in MENQOL score between a MBSR intervention group
and a waiting list control group at 20 weeks in naturally
post- and perimenopausal women,33 a statistical power of
80%, and an a of 0.05.33
Quality control
To improve consistency and uniformity of the MBSR train-
ing sessions, three meetings were organised with the train-
ers under the supervision of an experienced MBSR trainer
(MS), and adherence to the protocol was assessed by audio
recordings of 6/48 (12.5%) of all training sessions. Protocol
adherence was defined as the weighted average of agree-
ment between the specified and actual duration of the exer-
cise. Participant attendance was recorded by trainers at the
start of each session, and participants were asked to report
the frequency and duration of daily home exercises on
weekly evaluation forms during the intervention period.
Statistical analysis
In case of missing items in the questionnaires, scores were
calculated using mean imputation if at least 80% of the
answers had been given. Baseline characteristics were
described for each treatment arm using means and
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standard deviations for continuous variables and using fre-
quencies for categorical variables. The primary and sec-
ondary outcomes were analysed by linear mixed modelling
to allow for the inclusion of women with missing time
points for longitudinal data. The scores on the MENQOL,
FSDS, FSFI, and their subdomains at T0, T1, T2, and T3
were modelled as a function of the treatment arm, the
moment in time, and the interaction between the treatment
arm and the moment in time. An unstructured data matrix
was assumed because the data did not indicate another cor-
relation structure. All analyses were performed on an inten-
tion-to-treat basis. The normality of the outcome measures
will be determined by visual inspection of a quantile–quan-
tile (Q–Q) plot. We used SPSS 23 (IBM Corp., Armonk,
NY, USA) for all analyses. All P values were two-tailed and
considered significant if P < 0.05.
Results
Recruitment and attrition
Of the 365 women informed about the study, 218 women
completed and returned the questionnaires on the presence
and severity of menopausal symptoms (Figure 1); of these,
197 met the inclusion criteria and 66 agreed to participate
and be randomised to the MBSR (n = 34) and CAU
(n = 32) groups. One participant in the CAU group did not
return the questionnaire at T0 or at subsequent time points,
for unknown reasons, so baseline data were available for 65
participants (34 MBSR, 31 CAU). At inclusion, the average
age of the participants was 47.7  5.2 years, and 19 out of
65 (29%) women used HRT (Table 1). Furthermore, 17 out
of 65 women (26%) had a history of breast cancer.
Six participants did not complete the intervention, with
two citing scheduling conflicts, two citing that it was too
time consuming, and two citing that they were not expect-
ing any benefit. At each time point, at least 70% of the
participants returned their questionnaires, and the reasons
for non-response are shown in Figure 1. In total, 53
women completed the MENQOL questionnaire at T1,
resulting in a statistical power of 76%.
Quality control
Adherence by the trainers to the MBSR protocol, based on
the audio recordings of several training sessions, was 80%.
Participants receiving MBSR attended 79% of the MBSR
sessions. The patient-reported adherence to daily home-
work was 75% during the intervention period, with partici-
pants reporting practising for 33 minutes on average per
day.
Primary and secondary outcomes
Table 2 summarises the results of linear mixed modelling
of the primary and secondary outcomes as a function of
time, treatment, and interaction between time and treat-
ment. Figure 2 visualises the primary outcome estimates
per time point and treatment arm.
At randomisation (T0), 63% (41/65) of participants
reported five or more complaints with a bothersome score
of six or higher (scale ranged from one to eight, data not
shown). Statistically significant differences in improvements
were found for the MENQOL total score (T1, 0.56,
P = 0.04; T3, 0.56, P = 0.04), and for the vasomotor (T1,
0.93, P = 0.04; T3, 0.98, P = 0.02) and physical (T1, 0.65,
P = 0.01; T3, 0.69, P = 0.03) subscales in the MBSR group
compared with the CAU group at 3 and 12 months after
the start of the intervention (Table 2). At 6 months, there
was a non-significant trend for improvement in the MBSR
group compared with the CAU group (P = 0.31), but there
were no statistically significant differences in the psychoso-
cial and sexual subscales of the MENQOL between the
MBSR and CAU groups at any assessment point. A statisti-
cally non-significant but clinically relevant improvement
(≥1 improvement in MENQOL total score) was also seen
in 28.6% of the MBSR group compared with 16.7% of the
CAU group at T1.
Regarding the secondary outcomes, 94% (61/65) of
participants reported clinically relevant sexual dysfunction
and 65% (42/65) reported clinically relevant sexual dis-
tress at randomisation (T0; data not shown); however,
no statistically significant differences were observed
between the MBSR and CAU groups for the FSDS and
FSFI total scores or subscales at any assessment point
(Table 2).
After visual inspection of their respective Q–Q plots, the
MENQOL and FSDS could be considered to be normally
distributed, but some non-normality could be observed in
the distribution of FSFI scores at baseline (Figure S1).
Discussion
Main findings
In this randomised study, we showed that MBSR improved
menopause-specific quality of life over both the short- and
long-term in women with at least two moderate-to-severe
menopausal symptoms after RRSO; however, MBSR did
not improve sexual functioning or sexual distress.
Strengths and limitations
The main strengths of this study are its randomised con-
trolled design, the long-term follow-up over 12 months,
and that MBSR was conducted by certified trainers with
high protocol adherence. Furthermore, this study is the
first RCT to test a psychological intervention for alleviating
menopausal complaints after RRSO, and is among the first
to test the effect of that intervention on sexual symptoms
associated with menopause.
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The CAU group did not receive a blinded placebo
intervention because it was impossible to blind partici-
pants to treatment allocation, which could induce a pla-
cebo effect. The use of a non-active control group
receiving CAU and no other attention during the inter-
vention period means that there was no control for the
non-specific effects of MBSR (e.g. repeated contact with
MBSR trainers and other group participants). Although
no adverse effects were reported during the intervention,
this was not routinely monitored or recorded, so cannot
be excluded as a possibility. The FSFI questionnaire was
observed to have some non-normality which could have
resulted in an optimistic P-value estimation. As the FSFI
was not found to be statistically significantly improved in
the MBSR arm compared with the CAU arm, this would
not impact the conclusions of the study. Finally, only
one-third of the eligible women chose to participate in
this study, and therefore a self-selection bias is plausible
that could have caused an overestimation of the interven-
tion effect.
Figure 1. Population flowchart. *A total of 39 women responded that they had no interest in participating in the study without filling in the rest of
the questionnaire. #The T0, T1, T2, and T3 questionnaires were sent out at 0, 3, 6, and 12 months after randomisation, respectively.
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Interpretation
This is the first study reporting the long-term effects of
MBSR in women with menopausal symptoms after RRSO.
Consistent with previous studies, we showed short-term
improvement at three months (T1);32,33 however, our study
is the first to report a persisting effect after 1 year, with
improvement in menopause-specific quality of life at
12 months (T3) in the MBSR group compared with the
CAU group. Although there was improvement from baseline
in the MBSR group compared with the CAU group at the
intermediate period of 6 months (T2), this was not statisti-
cally significant. Given that the change in effect at 6 months
(T2) is small but in the same direction as the short- and
long-term significant effect, it is likely that this is merely a
statistical issue that could be solved with a larger sample size.
On the interpretation of the MENQOL score, no specific
studies have been published; however, the authors of the
MENQOL questionnaire have suggested that a relevant
clinical difference in MENQOL score could be a 0.5-point
change.38 This suggestion was based on previous publica-
tions that compared patient-rated relevant changes in
symptoms with the corresponding change on a seven-point
scale in other disease-specific quality-of-life questionnaires
(similar to the MENQOL questionnaire).43,44 A change of
0.5 or of 1.0 was equivalent to patients reporting their
symptoms to be ‘A little better’ and ‘Moderately better’,
respectively.43,44
In the current study the improvement in the total MEN-
QOL score was mainly the result of an improvement in the
subscales of vasomotor symptoms (i.e. burden caused by
hot flushes, night sweats, and sweating in general) and
physical symptoms (e.g. burden caused by stamina reduc-
tion, aches, and urination frequency). The average differ-
ence on a seven-point scale in the vasomotor subscale and
the physical subscale was 0.93 and 0.65 points, respectively.
Therefore, clinicians and patients could expect a modest to
moderate reduction of perceived burden (i.e. bother) by
vasomotor and physical symptoms of approximately 13
and 9%, respectively.
Clinicians and patients might want to be able to inter-
pret the clinical impact of MBSR in terms of a reduction
in the frequency of symptoms. The MENQOL question-
naire only measures bother by menopausal symptoms, not
frequency of menopausal symptoms. However some direc-
tion on the relationship between bother by and frequency
of menopausal symptoms can be given. In an earlier RCT
that recorded both the change in the frequency of hot
flushes and the change in the MENQOL score, an improve-
ment of approximately one point in the MENQOL score
was found together with a 45% reduction in the frequency
of hot flushes (representing an estimated reduction of
approximately four hot flushes per day); however, the con-
clusion that a one point change in the MENQOL score
represents the aforementioned reduction in hot flushes is
an oversimplification. Changes in the other symptom
domains or other (unknown) factors influence the total
MENQOL score as well, and therefore, the relationship
between MENQOL score and hot flush frequency could be
different in other circumstances.









47.7 (5.2) 47.0 (5.0) 48.5 (5.4)
BMI (kg/m2),
mean (SD)
26.4 (4.9) 26.6 (4.0) 26.2 (5.8)
Married or cohabiting, n (%)
No 7 (10.8) 1 (2.9) 6 (19.4)
Yes 58 (89.2) 33 (97.1) 25 (80.6)
Children, n (%)
No 10 (15.4) 2 (5.9) 8 (25.8)
Yes 55 (84.6) 32 (94.1) 23 (74.2)
Children at home, n (%)
No 16 (24.6) 4 (11.8) 12 (38.7)
Yes 49 (75.4) 30 (88.2) 19 (61.3)
Higher education, n (%)*
No 37 (56.9) 23 (67.6) 14 (45.2)
Yes 28 (43.1) 11 (32.4) 17 (54.8)
Employment status, n (%)
Unemployed 10 (15.4) 6 (17.6) 4 (12.9)
Part-time 39 (60.0) 19 (55.9) 20 (64.5)
Full-time 16 (24.6) 9 (26.5) 7 (22.6)
Smoker, n (%)
No 56 (86.2) 31 (91.2) 25 (80.6)
Yes 9 (13.8) 3 (8.8) 6 (19.4)
Alcohol consumption, n (%)
0–1 units/week 36 (55.4) 17 (50.0) 19 (61.3)
2–5 units/week 24 (36.9) 16 (47.1) 8 (25.8)
>6 units/week 5 (7.7) 1 (2.9) 4 (12.9)
Exercise behaviour, n (%)
<150 minutes/week 12 (18.5) 8 (23.5) 4 (12.9)
≥150 minutes/week 53 (81.5) 26 (76.5) 27 (87.1)
Underwent RRM, n (%)
No 34 (52.3) 15 (44.1) 19 (61.3)
Yes 31 (47.7) 19 (55.9) 12 (38.7)
Had breast cancer, n (%)
No 48 (73.8) 25 (73.5) 23 (74.2)
Yes 17 (26.2) 9 (26.5) 8 (25.8)
Current HRT use, n (%)
No 46 (70.8) 23 (67.6) 23 (74.2)
Yes 19 (29.2) 11 (32.4) 8 (25.8)
PHQ-2, mean (SD) 1.3 (1.3) 1.4 (1.4) 1.1 (1.1)
GAD-7, mean (SD) 5.5 (4.5) 5.0 (3.5) 5.9 (5.3)
n = 65: one participant did not return the questionnaire at T0 or at
subsequent time points, so baseline data were available for 65
participants.
*Higher education: (applied) university or higher.
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The baseline level of sexual dysfunction was very high in
this study, comparable with that reported after RRSO
in other research, but much higher than that reported in
the general population.27,45 Unfortunately, our MBSR inter-
vention did not improve this sexual dysfunction or distress.
In contrast to this, previous controlled studies of mindful-
ness-based therapy for low sexual desire and arousal have
found significant improvements in sexual functioning after
the intervention.46,47 Differences in study populations could
explain the results, because the sexual problems in previous
Table 2. Linear mixed modelling of the primary and secondary outcomes as a function of time, treatment, and interaction
T0 T1 T2 T3
MENQOL
Total score
CAU 3.8 (3.4–4.3) 3.8 (3.3–4.3) 3.7 (3.2–4.1) 3.9 (3.5–4.4)
MBSR 4.1 (3.7–4.5) 3.5 (3.0–3.9) 3.7 (3.2–4.1) 3.6 (3.1–4.0)
P 0.04* 0.31 0.04*
Vasomotor subscale
CAU 4.2 (3.6–4.8) 4.1 (3.5–4.8) 4.2 (3.5–4.8) 4.3 (3.7–4.9)
MBSR 4.5 (4.0–5.1) 3.5 (2.9–4.1) 3.8 (3.1–4.4) 3.6 (3.0–4.2)
P 0.04* 0.09 0.02*
Psychosocial subscale
CAU 3.7 (3.2–4.2) 3.6 (3.0–4.1) 3.6 (3.0–4.2) 3.8 (3.3–4.4)
MBSR 3.8 (3.3–4.3) 3.4 (2.8–3.9) 3.6 (3.0–4.2) 3.7 (3.1–4.3)
P 0.31 0.95 0.50
Physical subscale
CAU 3.5 (3.1–3.9) 3.6 (3.2–4.0) 3.5 (3.0–3.9) 3.8 (3.3–4.2)
MBSR 3.5 (3.2–3.9) 3.0 (2.6–3.4) 3.3 (2.9–3.7) 3.2 (2.7–3.6)
P 0.01* 0.32 0.03*
Sexual subscale
CAU 4.0 (3.1–4.8) 3.9 (3.0–4.7) 3.5 (2.7–4.3) 3.7 (2.9–4.4)
MBSR 4.4 (3.6–5.2) 4.1 (3.3–4.9) 4.2 (3.4–5.0) 4.0 (3.2–4.8)
P 0.66 0.39 0.77
FSDS
Total score
CAU 14.7 (10.7–18.7) 15.6 (10.7–20.4) 12.2 (7.8–16.6) 12.4 (7.5–17.2)
MBSR 16.9 (13.1–20.8) 16.7 (12.0–21.3) 17.2 (12.9–21.5) 17.6 (12.8–22.5)
P 0.65 0.17 0.26
FSFI
Total score
CAU 15.0 (11.9–18.1) 14.6 (11.3–17.8) 14.7 (11.3–18.2) 16.3 (13.0–19.6)
MBSR 14.8 (11.9–17.8) 15.7 (12.6–18.8) 14.4 (11.0–17.8) 16.8 (13.5–20.0)
P 0.40 0.92 0.75
Desire subscale
CAU 2.7 (2.3–3.1) 2.7 (2.3–3.1) 2.6 (2.2–3.1) 2.7 (2.2–3.1)
MBSR 2.7 (2.3–3.1) 2.5 (2.1–3.0) 2.5 (2.0–2.9) 2.7 (2.2–3.1)
P 0.63 0.66 0.97
Arousal subscale
CAU 2.8 (2.1–3.6) 2.8 (2.0–3.6) 2.8 (2.0–3.5) 3.2 (2.5–3.9)
MBSR 3.0 (2.3–3.7) 3.2 (2.5–3.9) 2.8 (2.1–3.6) 3.2 (2.5–4.0)
P 0.71 0.75 0.69
Lubrication subscale
CAU 2.9 (2.1–3.7) 2.7 (1.9–3.6) 3.0 (2.1–3.9) 3.0 (2.2–3.9)
MBSR 2.8 (2.1–3.6) 3.1 (2.3–3.9) 2.9 (2.1–3.8) 3.8 (2.9–4.7)
P 0.29 0.94 0.14
Orgasm subscale
CAU 3.0 (2.2–3.8) 2.8 (2.0–3.7) 2.8 (1.9–3.7) 3.4 (2.5–4.2)
MBSR 2.9 (2.1–3.7) 3.3 (2.5–4.1) 3.1 (2.2–4.0) 3.7 (2.8–4.6)
P 0.16 0.41 0.39
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studies were of a psychological nature (e.g. lack of desire or
low arousability), whereas the problems in the current popu-
lation may have been of mixed psychological and physiologi-
cal nature (e.g. vaginal discomfort and loss of desire as a
result of estrogen deprivation).46,47 Consistent with our
study, however, the earlier research also failed to show any
improvement in sexual distress.46,47 In a single-armed pilot
study, mindfulness-based therapy did improve sexual func-
tioning after RRSO, but that study used an intervention
specifically targeting sexual difficulties, rather than a general
MBSR protocol as we used in this study.48
It has been proposed that mindfulness facilitates a more
accepting, even-tempered state of being that helps to
decrease reactivity to stimuli.49 Therefore, MBSR could
work by reducing the degree to which vasomotor and
physical symptoms are experienced as problematic or
bothersome, in other words, by dampening the perceived
severity of symptoms.50 Indeed, it might be that MBSR
also primarily affects the psychological aspects of sexual
problems by improving cognitive appraisal rather than by
altering the actual physiological symptoms. This would
explain why a previous study on the effect of MBSR on
physiological arousal, as measured by vaginal photo-
plethysmography, did not find any improvement.46
Another hypothesis, however, is that by decreasing stress,
MBSR could diminish the frequency of hot flushes at a
physiological level, because stress is thought to lower the
threshold for heat-dissipation responses.50,51 Moreover, the
effect of MBSR on the physiological stress response has
been suggested by preliminary research indicating that it
produces statistically significant reductions in cortisol
levels and non-significant improvements in dehy-
droepiandrosterone-sulfate levels.52,53
Conclusion
This study indicates that MBSR improves short- and long-
term menopause-specific quality of life in women with
menopausal complaints after surgical menopause induced
by RRSO. We recommend that healthcare providers advo-
cate MBSR in conjunction with HRT; however, MBSR may
be especially relevant for breast cancer survivors or in other
settings when HRT is contraindicated.
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Table 2. (Continued)
T0 T1 T2 T3
Satisfaction subscale
CAU 3.6 (3.0–4.1) 3.6 (3.0–4.2) 3.7 (3.1–4.4) 3.9 (3.3–4.6)
MBSR 3.3 (2.7–3.8) 3.3 (2.7–3.9) 3.2 (2.6–3.9) 3.3 (2.7–3.9)
P 1.00 0.71 0.38
Pain subscale
CAU 2.8 (1.8–3.7) 2.7 (1.7–3.7) 2.6 (1.6–3.6) 3.2 (2.3–4.1)
MBSR 2.9 (2.0–3.8) 3.1 (2.2–4.0) 2.4 (1.5–3.4) 3.2 (2.2–4.1)
P 0.51 0.53 0.75
Results are presented as means and 95% confidence intervals. n = 65: one participant did not return the questionnaire at T0 or at subsequent
time points, resulting in baseline data being available for 65 participants. P values are reported for the group 9 time interactions in contrast with
T0 in a linear mixed model. *P < 0.05 corresponds to a statistically significant difference in the outcome measure between the MBSR and CAU
groups from T0.
Figure 2. MENQOL score estimates per time point and treatment arm.
The error bars represent standard errors.
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